Study of GI-102 and GIB-7 for aging in healthy adults and cancer survivors
Part of Cancer clinical trials.
This trial tests whether a combination of two drugs, GI-102 and GIB-7, can affect markers of aging in healthy people and in people who have had cancer. It aims to see if these drugs might help slow or improve aging-related changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You should be in generally good health without a life-threatening illness or disability.
- If you have had cancer, it must have been treated with curative intent and you must have been in remission for at least 12 months (or disease-free for 2 years or more). You cannot be on active cancer treatment except maintenance therapies like hormone therapy.
- You must agree to use effective contraception if you or your partner could become pregnant.
- You cannot have severe chronic diseases like advanced heart disease, kidney failure, or uncontrolled diabetes.
- You must be able to walk without a walker or wheelchair and perform daily activities independently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
This study looks at how to improve health and care support for people age 70 and older with gastrointestinal (GI) cancer. It may help by offering a structured way to address practical and emotional challenges that can affect aging and cancer care.
This study aims to improve care for younger adults (ages 18-50) with gastrointestinal (GI) tumors. Researchers will test ways to better support patients during and after treatment. If you are 18-50 and being treated for a GI tumor at Heidelberg University Hospital, you may be able to join.
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
This trial tests a probiotic supplement called iVS-1 to see if it can slow biological aging in healthy adults aged 40-75. Researchers want to learn if this probiotic may help support health as you age.
This trial tests a new drug called 7MW4911 for people with advanced gastrointestinal cancer that has not responded to standard treatments. The drug is designed to target and attack cancer cells, and doctors will check if it is safe and effective.
Hear when a new Cancer Survivors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.